MLchartDataset catalogue

anti-CD137/anti-FAP bispecific antibody BI 765179

Term · Oncology and biomedicine · MLC-T-ONC-010238

A bispecific antibody targeting both CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9) and fibroblast activation protein (FAP), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD137/anti-FAP bispecific antibody BI 765179 targets and binds to both FAP, expressed on cancer-associated fibroblasts (CAFs) in the tumor stroma, and CD137, expressed on the surface of immune cells including activated T-lymphocytes, natural killer (NK) cells and dendritic cells (DCs). The simultaneous binding of FAP and CD137 results in local clustering of FAP-expressing CAFs and CD137-expressing T cells in the tumor microenvironment (TME), local immune cell activation through the promotion of T-cell activation and cytokine release, and T-cell-mediated anti-tumor immune responses. CD137, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity. FAP, a membrane-bound serine protease overexpressed on CAFs, is minimally expressed on normal, healthy cells.

Table 1. Record
IdentifierMLC-T-ONC-010238
FieldOncology and biomedicine
Synonyms4-1BB x FAP bispecific antibody BI 765179; anti-4-1BB/anti-FAP bispecific antibody BI 765179; anti-4-1BB/FAP bispecific antibody BI 765179; anti-CD137/FAP bispecific antibody BI 765179; CD137 x FAP bispecific antibody BI 765179; CD137/FAP agonist BI 765179
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-010238",
  "term": "anti-CD137/anti-FAP bispecific antibody BI 765179",
  "field": "Oncology and biomedicine",
  "definition": "A bispecific antibody targeting both CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9) and fibroblast activation protein (FAP), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD137/anti-FAP bispecific antibody BI 765179 targets and binds to both FAP, expressed on cancer-associated fibroblasts (CAFs) in the tumor stroma, and CD137, expressed on the surface of immune cells including activated T-lymphocytes, natural killer (NK) cells and dendritic cells (DCs). The simultaneous binding of FAP and CD137 results in local clustering of FAP-expressing CAFs and CD137-expressing T cells in the tumor microenvironment (TME), local immune cell activation through the promotion of T-cell activation and cytokine release, and T-cell-mediated anti-tumor immune responses. CD137, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity. FAP, a membrane-bound serine protease overexpressed on CAFs, is minimally expressed on normal, healthy cells.",
  "synonyms": [
    "4-1BB x FAP bispecific antibody BI 765179",
    "anti-4-1BB/anti-FAP bispecific antibody BI 765179",
    "anti-4-1BB/FAP bispecific antibody BI 765179",
    "anti-CD137/FAP bispecific antibody BI 765179",
    "CD137 x FAP bispecific antibody BI 765179",
    "CD137/FAP agonist BI 765179"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-cd137-anti-fap-bispecific-antibody-bi-765179/"
}

Record 1,323 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.